An Extension Study of ANAVEX2-73 in Patients With Mild to Moderate Alzheimer's Disease

Trial Profile

An Extension Study of ANAVEX2-73 in Patients With Mild to Moderate Alzheimer's Disease

Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Nov 2017

At a glance

  • Drugs ANAVEX 2-73 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Sponsors Anavex Life Sciences
  • Most Recent Events

    • 04 Nov 2017 According to an Anavex Life Sciences media release, data from the first year of this trial will be presented at the 2017 Clinical Trials on Alzheimer's Disease (CTAD) Meeting.
    • 06 May 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top